The diagnosis and development of heparin-induced thrombocytopenia. Clinical and biological aspects;Diagnostic et gestion des thrombopenes induites par l'heparine: Aspects biologiques et cliniques

Revue des Maladies Respiratoires

Volumn 16, Issue 5 BIS, 1999, Pages 961-974

  Elalamy, I ^a   Page, Y ^b   Viallon, A ^b   Tardy, B ^b   Conard, J ^a   Helft, G ^c  

^a HÔTEL DIEU   (France)

^b SERVICE DE NEUROLOGIE   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Danaparoid; Heparin; Heparin induced thrombocytopenia; Hirudin; HIT; Thrombocytopenia; Thrombosis

Indexed keywords

DANAPAROID; HEPARIN; LEPIRUDIN; ANTICOAGULANT AGENT; CHONDROITIN SULFATE; DERMATAN SULFATE; DRUG DERIVATIVE; HEPARAN SULFATE; HIRUDIN DERIVATIVE; RECOMBINANT PROTEIN;

CLINICAL EXAMINATION; DISEASE CLASSIFICATION; DRUG MONITORING; EARLY DIAGNOSIS; HUMAN; HYPERSENSITIVITY; LABORATORY TEST; REVIEW; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; ANTICOAGULANT THERAPY; ARTICLE; CHEMICALLY INDUCED DISORDER; DIFFERENTIAL DIAGNOSIS; DRUG COMBINATION; PATHOPHYSIOLOGY;

ANTICOAGULANTS; CHONDROITIN SULFATES; DERMATAN SULFATE; DIAGNOSIS, DIFFERENTIAL; DRUG COMBINATIONS; HEPARIN; HEPARITIN SULFATE; HIRUDIN THERAPY; HIRUDINS; HUMANS; RECOMBINANT PROTEINS; THROMBOCYTOPENIA;

EID: 0033223304     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. ELALAMY I, HORELLOU MH, SAMAMA MM : Caractéristiques pharmacologiques des héparines. Sem Hôp Paris 1995;71:389-400.
2. AMIRAL J : Le facteur 4 plaquettaire, cible des anticorps antihéparine : application au diagnostic biologique de la thrombopénie induite par l'héparine. Ann Méd Int 1997;148: 142-9.
3. CHONG BH : Annotation: heparin-induced thrombocytopenia. Br J Haematol 1995;89:431-9.
4. GRUEL Y. Thrombopénies induites par les héparines: manifestations cliniques et physiopathologie. Presse Méd, 1998; 27:S7-S12
5. LASTER J, CIKRIT D, WALKER N, SILVER D : The heparin-induced thrombocytopenia : an update. Surg 1987;104: 763-70.
6. GRUEL Y, LANG M, DARNIGE L et al. : Fatal effect of re-exposure to heparin after previous heparin-associated thrombocytopenia and thrombosis. Lancet 1990;336:1077-8.
7. WARKENTIN TE, CHONG BH, GREINACHER A. Heparin-induced thrombocytopenia : toward a consensus. Thromb Haemost 1998;79:1-7.
8. PHELAN BK : Heparin-associated thrombosis without thrombocytopenia. Ann Intern Med 1983;99:637-8.
9. HACH-WUNDERLE V, KAINER K, SALZMANN G, MUELLER-BERGHAUS G, POETSCH B : Heparin-related thrombosis despite normal platelet counts in vascular surgery. Amer J Surg 1997;173:117-9.
10. WARKENTIN TE, LEVINE MN, HIRSCH J et al. : Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Eng J Med 1995;332:1330-5.
11. SCHMITT BP, ADELMAN B : Heparin-associated thrombocytopenia: a critical review and a pooled analysis. J Med Sci 1993;305:208-15.
12. TARDY B, PAGE Y, TARDY-PONCET B, COMTET C, ZENI F, BERTRAND JC : Thrombopénie induite par une héparine de bas poids moléculaire. Thérapie 1990;45:453.
13. EICHINGER S, KYRLE PA, BRENNER B et al. : Thrombocytopenia associated with low-molecular-weight heparin. Lancet 1991;337:1425-6.
14. LECOMPTE T, BOITEAU R, RICHARD X et al. : Thrombopénie grave sous tedelparine avec embolie pulmonaire et coagulopathie de consommation. Presse Méd 1991;20:563.
15. ROLAND JG, MASSADE E, SERRANO M, TOUZAIN F, FRANCO A : Thrombocytopénie sous héparine de bas poids moléculaire avec recherche d'anticorps anti-plaquettes positive en présence de Fraxiparine. Thérapie 1991;46:497-501.
16. WEITZ JI : Low-molecular-weight heparins. N Engl J Med 1997;337:688-98.
17. ELALAMY I, POTEVIN F, LECRUBIER C, BARA L, MARIE JP, SAMAMA MM : A fatal low molecular weight heparin associated thrombocytopenia after hip surgery : possible usefulness of PF4-heparin ELISA test. Blood Coag Fibrinolys 1996;7:665-71.
18. DECOUSUS H, LEIZOROVICZ A, PARENT F et al. (PREPIC STUDY) : A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med 1998;338:409-15.
19. SIMONNEAU G, SORS H, CHARBONNIER B et al. : A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997;337:663-9.
20. HEEGER PS, BACKSTROM JT : Heparin flushes and thrombocytopenia. Ann Intern Med 1986;105:143.
21. LASTER J, SILVER D : Heparin-coated catheters and heparin-induced thrombocytopenia. J Vasc Surg 1988;7:667-72.
22. MIKHAILIDIS DP, BARRADAS MA, MIKHAILIDIS AM et al. : Comparison of the effect of a conventional heparin and a low molecular weight heparinoid on platelet function. Br J Clin Pharmacol 1984;17:43-8.
23. RHODES GR, DIXON RH, SILVER D : Heparin-induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg Gynecol Obstet 1973;136:409-16.
24. AMIRAL J, BRIDEY F, DREYFUS M et al : Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992;68:95-6.
25. GREINACHER A, MICHELS I, MUELLER-ECKHARDT C : Heparin-associated thrombocytopenia : the antibody is not heparin specific. Thromb Haemost 1992;67:545-9.
26. AMIRAL J, BRIDEY F, WOLF M et al. : Antibodies to macro-molecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia : a study of 44 cases. Thromb Haemost 1995;73:21-8.
27. POUPLARD C, AMIRAL J, BORG J, VISSAC A, DELAHOUSSE B, GRUEL Y : Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoïd sodium (Orgaran). Br J Haematol 1997;99:273-80.
28. WARKENTIN TE, KELTON JG : A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502-7.
29. CINES DB, TOMASKI A, TANNENBAUM S : Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med 1987;316:581-9.
30. ASTER RH : Heparin-induced thrombocytopenia and thrombosis. N Engl J Med 1995;332:1374-6.
31. AMIRAL J, WOLF M, FISHER AM, BOYER NEUMAN C, VISSAC AM, MEYER D : Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 1996;92:954-9.
32. AMIRAL J, MARFAING-KOKA A, WOLF M et al. : Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood 1996;88:410-16.
33. ELALAMY I, LECRUBIER C, AMIRAL J, POTEVIN F, MARIE JP, SAMAMA MM : Discrepancies between heparin-platelet-induced antibodies (HPIA) test and platelet aggregation test (PAT) : other target for heparin induced antibodies? Thromb Haemost 1997;78,449 (abstract).
34. GRUEL Y : Thrombocytopénies induites par l'héparine : de la physiopathologie à Ia thérapeutique. Ann Méd Int 1997;148:136-41.
35. RASKOB GE, GEORGE JN : Thrombotic complications of antithrombotic therapy : a paradox with implications for clinical practice. Ann Intern Med 1997;127:839-41.
36. BOON DMS, MICHIELS JJ, STIBBE J, VAN VLIET HHDM, KUPPERS-KLUNE MC : Heparin-induced thrombocytopenia and antithrombotic therapy. Lancet 1994;344:1296.
37. SCHIELE F, VUILLEMENOT A, KRAMARZ P et al. : Use of recombinant Hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Haematol 1995;50:20-5.
38. TARDY-PONCET B : French experience in the use of Orgaran as an alternative antithrombotic treatment for patients with heparin induced thrombocytopenia. Thromb Haemost 1997;78:447 (abstract).
39. KING DJ, KELTON JG : Heparin-associated thrombocytopenia : diagnosis and treatment. Ann Intern Med 1986;100:535-40.
40. CARDOT F, BORG Y, GUEDON C, LEREBOURS E, COLIN R : Thrombose de la veine porte et thrombopénie à l'héparine. Gastroentérol Clin Biol 1991;15:172-3.
41. WARKENTIN TE, KELTON JG : Heparin-induced thrombocytopenia. Progress Hemost Thromb 1991;1:1-34.
42. WARKENTIN TE, ELAVATHIL LJ, HAYWARD CP, JOHNSTON MA, RUSSETT JI, KELTON JG : The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997;127:804-12.
43. HEWITT RL, AKERS DL, LEISSINGER CA, GILL JI, ASTER RH : Concurrence of anaphylaxis and acute heparin-induced thrombocytopenia in a patient with heparin-induced antibodies. J Vasc Surg 1998;28:561-5.
44. ERNEST D, FISHER MM : Heparin-induced thrombocytopenia complicated by bilateral adrenal haemorrhage, Intens Care Med 1991;17:238-40.
45. SLAUGHTER TF, GREENSBERG CS : Heparin-associated thrombocytopenia and thrombosis: implications for perioperative management. Anesthesiology 1997;87:667-75.
46. ELALAMY I, POTEVIN F, LECRUBIER C, AMIRAL J, MARIE JP, SAMAMA MM : Diagnostic biologique de la thrombopénie immuno-allergique à l'héparine (TIH) : comparaison des tests d'agrégation plaquettaire et ELISA « facteur 4 plaquettaire-héparine » (HPIA) chez 100 patients. Feuill Biol 1998;XXXIX,220:9-16.
47. NGUYEN P : Diagnostic et surveillance biologique des thrombopénies induites par l'héparine. Presse Méd 1998;27: S13-S17.
48. BACHELOT-LOZA C, SAFFROY R, LASNE D, CHATELLIER G, AIACH M, RENDU F : Importance of the FcγRIIa-Arg/His-131 polymorphism in heparin-induced thrombocytopenia diagnosis. Thromb Haemost 1998;79:523-8.
49. LECRUBIER C, LECOMPTE T, POTEVIN F, HORELLOU MH, CONARD J, SAMAMAM M : Platelet aggregation tests in 26 cases of heparin-induced thrombocytopenia. Methodological, diagnostic problems and therapeutic aspects. J Mal Vasc 1987;12:S128-S132.
50. GREINACHER A, AMIRAL J, DUHAMEL V, VISSAC A, KIEFEL V, MUELLER-ECKHARDT C. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced activation test and platelet factor4/heparin enzyme-linked immunosorbent assay. Transfusion 1994;34:381-5.
51. STEWART MW, ETCHES WS, BOSHKOV LK, GORDON PA : Heparin induced thrombocytopenia : an improved method of detection based on lumi-aggregometry. Br J Haematol 1995;91:173-7.
52. TOMER A : A sensitive and specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia. Br J Haematol 1997;98:648-56.
53. SAMAMA MM, ELALAMY I, LECRUBIER C et al. : Thrombopénie induite par l'héparine : intérêts et difficultés de l'identification d'un mécanisme immunologique. Bull Acad Nat Med 1998;182:1517-33.
54. AREPALLY G, REYNOLDS C, TOMASKI et al. : Comparison of PF4/heparin ELISA assay with 14C-serotonin release assay in the diagnosis heparin induced thrombocytopenia : Am J Clin Pathol 1995;104:648-54.
55. BAUER TL, AREPALLY G, KONKLE BA et al. : Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 1997;95:1242-6.
56. KAPPERS-KLUNNE MC, BOON DMS, HOP WCJ et al. : Heparin-induced thrombocytopenia and thrombosis : a prospective analysis of the incidence in patients with heart and cerebrovascular diseases. Br J Haematol 1997;96:442-6.
57. TROSSAERT M, GAILLARD A, COMMIN PL, AMIRAL J, VISSAC AM, FRESSINAUD E : High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br J Haematol 1998;101:653-5.
58. POUPLARD C, MAY MA, IOCHMANN S et al. : Antibodies to platelet factor4-heparin after cardiopulmonary bypass in patints anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparin-induced thrombocytopenia. Circulation 1999;99:2530-6.
59. WALENGA JM, JESKE WP, FASANELLA AR et al. : Laboratory tests for the diagnosis of heparin-induced thrombocytopenia. Semin Thromb Hemost 1999;25(suppl 1):43-9.
60. NEWMAN PM, SWANSON RL, CHONG BH : Heparin-induced thrombocytopenia : IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb Haemost 1998;80:292-7.
61. IZBAN KF, LIETZ HW, HOPPENSTEADT DA, JESKE WP, FAREED J, WALENGA J : Comparison of two PFA/heparin Elisa assays for the laboratory diagnosis of heparin-induced thrombocytopenia. Sem Thromb Haemost 1999;25(suppl): 51-6.
62. SHERIDAN D, CARTER C, KELTON JG : A diagnostic for heparin induced thrombocytopenia. Blood 1986,67, 27-30.
63. HULL RD, RASKOB GE, ROSENBLOOM D et al. : Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990;322:1260-4.
64. RECOMMANDATIONS DU GEHT : utilisation des héparines en pratique médicale courante. Sang Thrombose Vaisseaux 1996;8:5-13.
65. HORELLOU MH, CONARD J, LECRUBIER C et al. : Persistent Heparin induced thrombocytopenia despite therapy with low molecular weight heparin. Thromb Haemostas 1984;51:134.
66. MAGNANI HN : Orgaran (Danaparoïd sodium) use in the syndrome of heparin-induced thrombocytopenia. Platelets 1997;8:74-81.
67. WILDE M, MARKHAM A : Danaparoid : a review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs 1997;54:903-24.
68. VUN CM, EVANS S, CHONG BH : Cross-reactivity study of low molecular weight heparins and heparinoid in heparin-induced-thrombocytopenia. Thromb Res 1996;81:525-32.
69. TARDY B, TARDY-PONCET B, VIALLON A, PIOT M, MAZET E : Fatal danaparoïd-sodium induced thrombocytopenia and arterial thromboses. Thromb Haemost 1998;80:530.
70. TARDY-PONCET B, REYNAUD J, TARDY B et al. : Thrombopénie induite par l'héparine : traitement par l'ORG 10172 : tolérance et efficacité. Presse Méd 1996;25:751-5.
71. TARDY-PONCET B, TARDY B, REYNAUD J et al. : Efficacy and safety of danaparoïd sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia. Chest 1999;115:1616-20.
72. GITLIN SD, DEEB GM, YANN C, SCHMAIER AH : Intraoperative monitoring of danaparoid sodium anticoagulation during cardiovascular operations. J Vasc Surg 1998;27:568-75.
73. CHAMBERLAIN JR, LEWIS B, LEYA F et al. : Successful treatment of heparin-associated thrombocytopenia and thrombosis using Hirulog. Can J Cardiol 1995;11:511-4.
74. SCHIELE F, LINDGAERDE F, ERIKSSON H et al. : Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs : a multicentre prospective dose-ranging randomized trial. International Multicentre Hirudin Study Group. Thromb Haemost 1997;77:834-8.
75. SCHMIDT O, LANG W : Heparin induced thrombocytopenia with thromboembolic arterial occlusion treated with recombinant hirudin. N Eng J Med 1997;337:1389.
76. CAMEZ A : REFLUDAN : Le premier traitement de la thrombopénie induite par l'héparine (TIH) de type II. Presse Méd 1998;27:S28-S30.
77. LASNE D, BOYER S, AIACH M, ALHENC-GELAS M : Surveillance biologique du traitement par le Refludan chez 4 patients présentant une suspicion de thrombopénie induite par l'héparine. Réunion du GEHT, Octobre 1998.
78. HEUBERGER L, ALESSI MC, RAUFAST D et al. : Traitement des TIH par hirudine : a propos de 3 cas. Réunion du GEHT, Octobre 1998.
79. WARKENTIN TE : Heparin-induced thrombocytopenia. Pathogenesis, frequency, avoidance and management. Drug Safety 1997;17:325-41.
80. ELALAMY I, LECRUBIER C, POTEVIN F et al. : Absence of in vitro Cross-reaction of Pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia. Thromb Haemost 1995;74:1384-5.
81. AMIRAL J, LORMEAU JC, MARFAING-KOKA A et al. : Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 1997;8:114-7.
82. R (argatroban) in patients with heparin-induced thrombocytopenia and thrombosis syndrome. Semin Thromb Hemost 1997;23:197-02.
83. MAGNANI HN, BEIJERING RJR, TEN CATE JW et al. : Orgaran anticoagulation for cardioplulmonary bypass in patients with heparin-induced thrombocytopenia In Pifarre editor. New anticoagulants for the cardiovascular patient. Philadelphia. Hanley & Belfus Inc 1997: 487-500.
84. KAPPA JR, HORN MDK, FISHER CA, COTTRELL ED, ELLISON N, ADDONIZIO VP : Efficacy of iloprost (ZK 36374) versus aspirin in preventing heparin-induced platelet activation during cardiac operations. J Thorac Cardiovasc Surg 1987;94:405-13.
85. GRUEL Y, LERMUSIAUX P, LANG M et al. : Usefulness of anti-platelet drug iloprost in the management of heparin-associated thrombocytopenia and thrombosis. Ann Vasc Surg 1991;5:552-5.
86. ELALAMY I, POTEVIN F, LECRUBIER C, BARA L, MARIE JP, SAMAMA MM : In vitro inhibitory effect of ReoPro on human platelet aggregation: specific results in heparin-associated thrombocytopenia. Haemostasis 1996 suppl (abstract).
87. FIESSINGER JN, AIACH M, RONCATO M, DEBURE C, GAUX JC : Critical ischemia during heparin-associated thrombocytopenia. Treatment by intra-arterial streptokinase. Thromb Res 1984;33:235-8.
88. POULLIN P, PIERI A, LEFEVRE P : Heparin-induced thrombocytopenia with thrombosis : successful treatment with plasma exchange. Br J Haematol 1998;102:630-1.
89. FRAME JN, MUVLEY KP, PHARES JC, ANDERSON MJ : Correction of severe heparin-associated thrombocytopenia with intravenous immunoglobulin. Ann Intern Med 1989;111:946-7.
90. WINDER A, SHOENFELD Y, HOCHMAN R, KEREN G, LEVY Y, ELDOR A : High-dose intravenous gamma-globulins for heparin-induced thrombocytopenia : a prompt response. J Clin Immunol 1998;18:330-4.
91. DEMERS C, GINSBERG J, BRILL-EDWARDS P et al. : Rapid anti-coagulation using ancrod for heparin-induced thrombocytopenia. Blood 1991;78:2194-7.
92. ALMEIDA JI, COATS R, LIEM TK, SILVER D : Reduced morbidity and mortality rates of the heparin-induced thrombocytopenia syndrome. J Vasc Surg 1998;27:309-16.